MX352328B - Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. - Google Patents

Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Info

Publication number
MX352328B
MX352328B MX2015003139A MX2015003139A MX352328B MX 352328 B MX352328 B MX 352328B MX 2015003139 A MX2015003139 A MX 2015003139A MX 2015003139 A MX2015003139 A MX 2015003139A MX 352328 B MX352328 B MX 352328B
Authority
MX
Mexico
Prior art keywords
treating
methods
deficiency
testoterone
same
Prior art date
Application number
MX2015003139A
Other languages
English (en)
Inventor
E Dudley Robert
P Constantinides Panayiotis
Original Assignee
Clarus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarus Therapeutics Inc filed Critical Clarus Therapeutics Inc
Publication of MX352328B publication Critical patent/MX352328B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Se proporciona una formulación farmacéutica de undecanoato de testosterona. También se proporcionan métodos para tratar una deficiencia de testosterona o sus síntomas con las formulaciones novedosas.
MX2015003139A 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. MX352328B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2010/030788 WO2011129812A1 (en) 2010-04-12 2010-04-12 Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same

Publications (1)

Publication Number Publication Date
MX352328B true MX352328B (es) 2017-11-21

Family

ID=43074118

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015003139A MX352328B (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
MX2012011952A MX2012011952A (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012011952A MX2012011952A (es) 2010-04-12 2010-04-12 Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.

Country Status (17)

Country Link
EP (2) EP2803350B1 (es)
JP (1) JP5992397B2 (es)
KR (2) KR101460871B1 (es)
CN (1) CN102883710B (es)
AU (1) AU2010351080B2 (es)
BR (1) BR112012025961B1 (es)
CA (1) CA2795908C (es)
DK (1) DK2558073T3 (es)
ES (1) ES2525520T3 (es)
HK (1) HK1180593A1 (es)
IL (1) IL222315A (es)
MX (2) MX352328B (es)
NZ (1) NZ602821A (es)
RU (1) RU2012142997A (es)
SG (1) SG184540A1 (es)
WO (1) WO2011129812A1 (es)
ZA (1) ZA201207517B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
KR101432466B1 (ko) 2005-04-15 2014-08-21 클라루스 쎄러퓨틱스, 아이엔씨. 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
ES2638981T3 (es) 2012-12-20 2017-10-24 Solural Pharma ApS Forma de dosificación oral sólida del derivado de testosterona
AU2014232911B2 (en) * 2013-03-15 2019-04-04 Tolmar, Inc. Methods of treating testosterone deficiency
ES2749588T3 (es) 2013-10-07 2020-03-23 Antares Pharma Inc Modulación de hematocrito mediante inyección de testosterona a chorro asistida por aguja
BR112016028192A2 (pt) * 2014-06-17 2017-08-22 Merck Sharp & Dohme gerritdina g. schoonus-gerritsma
WO2015193380A2 (en) 2014-06-19 2015-12-23 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2016022936A1 (en) * 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
ES2877107T3 (es) 2014-08-28 2021-11-16 Univ Texas Formulaciones de testosterona y procedimientos de tratamiento con ellas
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
WO2016049382A1 (en) * 2014-09-24 2016-03-31 Lipocine Inc. Compositions and their use in oral dosing regimens
US20160361322A1 (en) * 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA3078723A1 (en) * 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy
WO2018213772A1 (en) * 2017-05-18 2018-11-22 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
CN108524485A (zh) * 2018-02-24 2018-09-14 中山大学 一种猴睾酮缺乏模型的建立方法
US20200197412A1 (en) * 2018-12-20 2020-06-25 Clarus Therapeutics, Inc. Methods of treating testosterone deficiency
JP7144346B2 (ja) 2019-03-20 2022-09-29 日立Ｇｅニュークリア・エナジー株式会社 遠隔測定システム、および、遠隔測定方法
US11564933B2 (en) * 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
WO2020210501A1 (en) * 2019-04-12 2020-10-15 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents
US20220265678A1 (en) * 2019-10-30 2022-08-25 Marius Pharmaceuticals Llc Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
DK1189620T3 (da) * 1999-04-01 2004-08-16 Akzo Nobel Nv Formulering indeholdende testosteronundecanoat og amerikansk olie
US20020102301A1 (en) 2000-01-13 2002-08-01 Joseph Schwarz Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof
WO2006013369A2 (en) * 2004-08-04 2006-02-09 Camurus Ab Compositions forming non-lamellar dispersions
GB0417388D0 (en) * 2004-08-04 2004-09-08 Camurus Ab Composition
CN101217963A (zh) * 2005-04-15 2008-07-09 克劳拉斯医疗有限公司 疏水性药物给药系统及含有疏水性药物的组合物
KR101432466B1 (ko) * 2005-04-15 2014-08-21 클라루스 쎄러퓨틱스, 아이엔씨. 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions

Also Published As

Publication number Publication date
SG184540A1 (en) 2012-11-29
EP2558073B1 (en) 2014-09-10
EP2558073A1 (en) 2013-02-20
IL222315A (en) 2017-07-31
MX2012011952A (es) 2013-02-07
NZ602821A (en) 2014-07-25
KR101460871B1 (ko) 2014-11-11
AU2010351080B2 (en) 2014-08-28
KR101607034B1 (ko) 2016-03-28
KR20140012215A (ko) 2014-01-29
ES2525520T3 (es) 2014-12-26
BR112012025961A2 (pt) 2018-05-15
IL222315A0 (en) 2012-12-31
ZA201207517B (en) 2013-06-26
RU2012142997A (ru) 2014-06-20
WO2011129812A1 (en) 2011-10-20
BR112012025961B1 (pt) 2021-06-15
HK1180593A1 (en) 2013-10-25
EP2803350A1 (en) 2014-11-19
EP2803350B1 (en) 2017-09-20
KR20130074770A (ko) 2013-07-04
JP2013523880A (ja) 2013-06-17
CN102883710A (zh) 2013-01-16
AU2010351080A1 (en) 2012-11-01
DK2558073T3 (en) 2014-12-08
JP5992397B2 (ja) 2016-09-14
CA2795908A1 (en) 2011-10-20
CA2795908C (en) 2015-10-13
CN102883710B (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
HRP20190368T1 (hr) Derivati arilmetoksi izoindolina i pripravci koji ih sadrže te postupci njihove uporabe
WO2012055567A3 (en) Use of malononitrilamides in neuropathic pain
WO2012030993A3 (en) Skin compositions and methods of use thereof
AU333421S (en) Showerhead
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
IL232515A0 (en) nadph 4 oxidase inhibitors and pharmaceutical preparations containing them
EP2528603A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS
WO2011106297A3 (en) Compositions and methods for the diagnosis and treatment of tumor
IN2014DN07483A (es)
EP2464383A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF FLU
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EP2385769A4 (en) QUICKLY SOLUBLE VITAMIN FORMULATION AND METHOD FOR THEIR USE
EP2560614A4 (en) PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION
UY34455A (es) Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada
EP4233915A3 (en) Modified release formulations of viloxazine
WO2008153784A3 (en) Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors
HK1196765A1 (zh) 口服睾酮酯製劑以及包含其的治療睾酮缺乏症的方法
IL222642A0 (en) Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males
UA59396U (ru) Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью
WO2011161465A3 (en) Composition for treatment of skin
UA47350U (en) use of ethyl ester of N-[(2-oxoindolinelyden-3)-2-oxyacetyl]-aaminoacetic acids as nootropic and anxyolitic agent
AU334689S (en) Display stand and trays
AU2010903965A0 (en) Formulation and method for the treatment of timber
AU2009901952A0 (en) Methods and compositions for the promotion of wound healing